Commentary: Oncologic drugs in patients with organ dysfunction: A summary

Oncologist

Volumn 12, Issue 9, 2007, Pages 1070-1083

  Superfin, Diana ^a   Iannucci, Andrea A ^a   Davies, Angela M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Chemotherapy; Dysfunction; Hepatic; Renal

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; NAVELBINE; OXALIPLATIN; OXAZAPHOSPHORINE DERIVATIVE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSFORMATION; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; MUCOSA INFLAMMATION; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMATITIS; URINARY EXCRETION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; DNA TOPOISOMERASES; HUMANS; KIDNEY; KIDNEY DISEASES; LIVER; LIVER DISEASES; PROSPECTIVE STUDIES;

EID: 35548935226     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-9-1070     Document Type: Review

References (62)

1. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
2. Donelli MG, Zucchetti M, Munzone E et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33-46.
3. Mano MS, Cassidy J, Canney P. Liver metastases from breast cancer: Management of patients with significant liver dysfunction. Cancer Treat Rev 2005;31:35-48.
4. Ghobrial IM, Wolf RC, Pereira DL et al. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc 2004;79:169-175.
5. Perry MC. Chemotherapeutic agents and hepatotoxicity. Semin Oncol 1992;19:551-565.
6. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005;19:1057-1063; discussion 1063-1064, 1069.
7. Benjamin RS. Pharmacokinetics of Adriamycin (NSC-123127) in patients with sarcomas. Cancer Chemother Rep 1974;58:271-273.
8. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy - efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974;33:19-27.
9. Gurevich I, Akerley W. Treatment of the jaundiced patient with breast carcinoma. Case report and alternate therapeutic strategies. Cancer 2001;91:660-663.
10. Brenner DE, Wiernik PH, Wesley M et al. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 1984;53:1042-1048.
11. Zanette L, Zucchetti M, Freshi A et al. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 1990;30:307-316.
12. Camaggi CM, Strocchi E, Carisi P et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: A crossover study. Cancer Chemother Pharmacol 1992;30:307-316.
13. Twelves CJ, Dobbs NA, Michael Y et al. Clinical pharmacokinetics of epirubicin: The importance of liver biochemistry Tests. Br J Cancer 1992;66:765-769.
14. Dobbs NA, Twelves CJ, Gregory W et al. Epirubicin in patients with liver dysfunction: Development and evaluation of a novel dose modification scheme. Eur J Cancer 2003;39:580-586.
15. Ralph LD, Thomson AH, Dobbs NA et al. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Cancer Chemother Pharmacol 2003;52:34-40.
16. Hande KR, Wolff SN, Greco FA et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990;8:1101-1107.
17. Arbuck SG, Douglass HO, Crom WR et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986;4:1690-1695.
18. D'Incalci M, Rossi C, Zucchetti M et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986;46:2566-2571.
19. Aita P, Robieux I, Sorio R et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999;43:287-294.
20. Joel SP, Shah R, Clark PI et al. Predicting etoposide toxicity: Relationship to organ function and protein binding. J Clin Oncol 1996;14:257-267.
21. Stewart CF. Use of etoposide in patients with organ dysfunction: Pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994;34(suppl):S76-S83.
22. Raymond E, Boige V, Faivre S et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002;20:4303-4312.
23. Venook AP, Enders Klein C, Fleming G et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783-1790.
24. O'Reilly S, Rowinsky E, Slichenmyer W et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Nat Cancer Inst 1996;88:817-824.
25. Doroshow JH, Synold TW, GandaraDet al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003;30(suppl 15):14-19.
26. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780-2787.
27. Desai ZR, Van den Berg HW, Bridges JM et al. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982;8:211-214.
28. Chong CDK, Logothetis CJ, Savaraj N et al. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol 1988;28:714-718.
29. Robieux I, Sorio R, Borsatti E et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996;59:32-40.
30. Panday VR, Huizing MT, Willemse PH et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997;24(suppl 11):S11-34-S11-38.
31. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998;16:1811-1819.
32. Francis P et al. Pharmacodynamics of docetaxel in patients with liver metastases. Proc Am Soc Clin Oncol 1994;13:138.
33. Burris HA. Optimal use of docetaxel (Taxotere): Maximizing its potential. Anticancer Drugs 1996;7(suppl 2):25-28.
34. Sanofi-Aventis. Taxotere® (docetaxel) [package insert]. Prescribing information as of October 2006. Bridgewater, NJ: Sanofi-Aventis, 2006.
35. Fleming GF, Schilsky RL, Schumm LP et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol 2003;14:1142-1147.
36. Twelves C, Glynne-Jones R, Cassidy J et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999;5:1696-1702.
37. Smith GA, Damon LE, Rugo HS et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997;15:833-839.
38. Bauer S, Hagen V, Pielken HJ et al. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anticancer Drugs 2002;13:847-849.
39. Eckel F, von Delius S, Dobritz F et al. Pharmacokinetic (PK) and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2005;23:4135.
40. Novartis Pharmaceuticals Corporation. Gleevec® (imatinib mesylate) [package insert]. Prescribing information as of November 2006. East Hanover, NJ: Novartis, 2006.
41. Takimoto CH, Liu PY, Lenz H et al. A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group trial. Proc Am Soc Clin Oncol 2006;24:2004.
42. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev 1995;21:33-64.
43. Joel S, Clark P, Slevin M et al. Renal function and etoposide pharmacokinetics: Is dose modification necessary? Proc Am Soc Clin Oncol 1991;10:103.
44. Pfluger KH, Hahn M, Holz JB et al. Pharmacokinetics of etoposide: Correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 1993;31:350-356.
45. Gallo JM, Laub PB, Rowinsky EK et al. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000;18:2459-2467.
46. GlaxoSmithKline. Hycamtin® (topotecan hydrochloride) [package insert]. Prescribing information as of July 2006. Philadelphia: GlaxoSmithKline, 2006.
47. Takimoto CH, Remick SC, Sharma S et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2003;21:2664-2672.
48. Takimoto CH, Remick SC, Sharma S et al. Administration of oxaliplatin to patients with renal dysfunction: A preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003;30(suppl 15):20-25.
49. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
50. Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002;49:225-234.
51. Dorr RT, Van Hoff DD. Cancer Chemotherapy Handbook, Second Edition Norwalk, CT: Appleton & Lange, 1994.
52. Breedveld P, Zelcer N, Pluim D et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804-5811.
53. Vakily M, Amer F, Kukulka MJ et al. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 2005;45:1179-1186.
54. Bramwell V, Calvert RT, Edwards G et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979;3:253-259.
55. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981;19:443-451.
56. Haubitz M, Bohnenstengel F, Brunkhorst R et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002;61:1495-1501.
57. Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: Its relationship to renal dysfunction. Med Pediatr Oncol 1984;12:313-317.
58. Mita AC, Sweeney CJ, Baker SD et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-562.
59. Pappas P, Karavasilis V, Briasoulis E et al. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol 2005;56:358-360.
60. Mulkerin D, Remick S, Ramanathan RK et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. Proc Am Soc Clin Oncol 2006;24:2032.
61. Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195-1200.
62. Takimoto CH, Mita AC. Design, conduct, and interpretation of organ impairment studies in oncology patients. J Clin Oncol 2006;24:3509-3510.